{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:53:51Z","timestamp":1778241231806,"version":"3.51.4"},"reference-count":42,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.01669","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T08:28:30Z","timestamp":1511771310000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Anti-idiotypic Antibodies against BP-IgG Prevent Type XVII Collagen Depletion"],"prefix":"10.3389","volume":"8","author":[{"given":"Mayumi","family":"Kamaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Toyonaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Ujiie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jaad.2006.06.029","article-title":"High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases","volume":"56","author":"Segura","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1046\/j.1365-2133.1999.02817.x","article-title":"High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases","volume":"140","author":"Harman","year":"1999","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1046\/j.1365-2230.2001.00779.x","article-title":"A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders","volume":"26","author":"Jolles","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s12016-009-8153-y","article-title":"High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases","volume":"38","author":"Ishii","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3109\/08916934.2011.606452","article-title":"Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update","volume":"45","author":"Czernik","year":"2012","journal-title":"Autoimmunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/jid.2014.453","article-title":"Effects of intravenous immunoglobulins on mice with experimental epidermolysis bullosa acquisita","volume":"135","author":"Hirose","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3389\/fimmu.2014.00674","article-title":"Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all?","volume":"5","author":"Nagelkerke","year":"2015","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/0896-8411(92)90153-H","article-title":"Analysis of anti-idiotypic antibodies against anti-microsomal antibodies in patients with thyroid autoimmunity","volume":"5","author":"Tandon","year":"1992","journal-title":"J Autoimmun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1365-2249.1991.tb05631.x","article-title":"Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis","volume":"83","author":"Rossi","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1365-2249.2010.04265.x","article-title":"Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris","volume":"162","author":"Mimouni","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/BF00918187","article-title":"Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin","volume":"11","author":"Evans","year":"1991","journal-title":"J Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/intimm\/dxm052","article-title":"The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model","volume":"19","author":"Blank","year":"2007","journal-title":"Int Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/intimm\/dxf099","article-title":"Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus","volume":"14","author":"Shoenfeld","year":"2002","journal-title":"Int Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid","volume":"95","author":"Liu","year":"1995","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1172\/JCI3693","article-title":"A critical role for neutrophil elastase in experimental bullous pemphigoid","volume":"105","author":"Liu","year":"2000","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3389\/fimmu.2017.00484","article-title":"Eosinophils in autoimmune diseases","volume":"8","author":"Diny","year":"2017","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/jid.2008.305","article-title":"IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment","volume":"129","author":"Iwata","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/exd.12146","article-title":"Bullous pemphigoid: role of complement and mechanisms for blister formation within the lamina lucida","volume":"22","author":"Iwata","year":"2013","journal-title":"Exp Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.4049\/jimmunol.1003402","article-title":"Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner","volume":"188","author":"Natsuga","year":"2012","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/1523-1747.ep12470554","article-title":"Effects of pemphigus antibody on the regeneration of cell-cell contact in keratinocyte cultures grown in low to normal Ca++ concentration","volume":"89","author":"Kitajima","year":"1987","journal-title":"J Invest Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1046\/j.1523-1747.2002.01720.x","article-title":"Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin","volume":"118","author":"Sitaru","year":"2002","journal-title":"J Invest Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1600-0625.2007.00564.x","article-title":"Experimental models of epidermolysis bullosa acquisita","volume":"16","author":"Sitaru","year":"2007","journal-title":"Exp Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0002-9440(10)61239-4","article-title":"Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus","volume":"167","author":"Arredondo","year":"2005","journal-title":"Am J Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1046\/j.1468-3083.2003.00714.x","article-title":"Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid","volume":"17","author":"Sami","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/j.1365-2133.2009.09034.x","article-title":"An \u2018n-of-1\u2019 placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris","volume":"160","author":"Arnold","year":"2009","journal-title":"Br J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/j.1468-3083.2011.04205.x","article-title":"Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: clinical outcome and post-treatment long-term follow-up","volume":"26","author":"Ahmed","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1684\/ejd.2012.1717","article-title":"High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid","volume":"22","author":"Gaitanis","year":"2012","journal-title":"Eur J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/path.4023","article-title":"Genetic identification and functional validation of Fc\u03b3RIV as key molecule in autoantibody-induced tissue injury","volume":"228","author":"Kasperkiewicz","year":"2012","journal-title":"J Pathol"},{"key":"B36","doi-asserted-by":"crossref","first-page":"CD002292","DOI":"10.1002\/14651858.CD002292.pub3","article-title":"Interventions for bullous pemphigoid","volume-title":"Cochrane Database of Systematic Reviews","author":"Kirtschig","year":"2010"},{"key":"B37","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous pemphigoid: a review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nm1496","article-title":"Humanization of autoantigen","volume":"13","author":"Nishie","year":"2007","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jaut.2008.08.009","article-title":"Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model","volume":"31","author":"Liu","year":"2008","journal-title":"J Autoimmun"},{"key":"B40","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archderm.136.2.174","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid","volume":"136","author":"Schmidt","year":"2000","journal-title":"Arch Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0923-1811(02)00109-3","article-title":"BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid","volume":"30","author":"Kobayashi","year":"2002","journal-title":"J Dermatol Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/1523-1747.ep12337492","article-title":"Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies","volume":"109","author":"Zillikens","year":"1997","journal-title":"J Invest Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01669\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T08:28:36Z","timestamp":1511771316000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01669\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2017.01669"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.01669","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,27]]},"article-number":"1669"}}